Partners

Sistema PJSFC is a publicly traded diversified Russian holding company in the sectors of telecommunications and digital services, IT and high technologies, e-commerce, paper and packaging, agriculture, construction and real estate, medical and pharmacy services, hospitality and others. The corporation was founded in 1993. Revenue in 2023 was RUB 1231,6 billion; total assets equaled RUB 2,8 trillion as of 31 December 2024. Sistema's ordinary shares are listed under the "AFKS" ticker on the Moscow Exchange.

Tagir Sitdekov - President of Sistema PJSFC

Tagir Sitdekov

Tagir Sitdekov graduated from the Russian Economic Academy of Plekhanov in 2001 and earned an Executive MBA from the University of Chicago Booth School of Business in 2012.

He began his career at PwC, consulting mining and energy clients.

In 2003, he became CFO at Sochi TPP, handling financial planning and risk management.

From 2010 to 2021, he held senior management positions in investment funds.

In 2021, he was appointed Managing Partner at Sistema PJSFC, where his responsibilities included attracting investors, finding new investment opportunities, developing and monetizing portfolio assets. In particular, Tagir Sitdekov oversaw medical and pharmaceutical assets as well as biotech, and was responsible for business strategy, forming collective management bodies and appointing company heads.

Since 2022, he serves as President of Sistema PJSFC, focusing on investment opportunities, asset growth, monetization, and capital allocation.

The modern, dynamically developing Russian pharmaceutical company, one of the leaders in the pharmaceutical industry of the Russian Federation in terms of growth rates.

Skopinpharm is a developer and manufacturer of medicines, one of the leading suppliers under the program of 14 high-cost nosologies in accordance with the Ministry of Health of the Russian Federation orders. Skopinpharm offers a range of medications under the regional preferential insurance program, and is also one of the main suppliers of the Circle of Good Foundation for helping children with serious and life-threatening illnesses. The company's turnover amounted to more than 44.1 billion rubles by 2024.

The company operates in the following key areas: manufacture of plasma-derived medicinal products, cytostatics, and medicinal products used for the treatment of various oncological diseases. As part of developing these business areas, the company has constructed new manufacturing and storage buildings, performs technology transfer of unique pharmaceutical manufacturing processes, and has built a plasma storage facility with a laboratory unit, which will ensure proper storage of plasma intended for fractionation (raw materials for the manufacture of human plasma-derived medicinal products).

At the same time, in partnership with health authorities, a modern system for the procurement of blood plasma is being created and a voluntary donation program is being developed.

Skopinpharm actively supports the training and advanced training of pharmaceutical industry specialists and is one of the founders of the Academy of Good Practices of the EAEU.